NTV Asset Management LLC Reduces Holdings in Pfizer Inc. (NYSE:PFE)

NTV Asset Management LLC trimmed its position in shares of Pfizer Inc. (NYSE:PFE) by 5.2% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 64,994 shares of the biopharmaceutical company’s stock after selling 3,530 shares during the quarter. NTV Asset Management LLC’s holdings in Pfizer were worth $1,871,000 as of its most recent filing with the SEC.

Several other large investors have also recently made changes to their positions in PFE. Charles Schwab Investment Management Inc. boosted its stake in Pfizer by 10.9% during the third quarter. Charles Schwab Investment Management Inc. now owns 95,772,746 shares of the biopharmaceutical company’s stock worth $3,161,261,000 after buying an additional 9,393,992 shares during the last quarter. Morgan Stanley boosted its stake in Pfizer by 0.4% during the third quarter. Morgan Stanley now owns 84,927,802 shares of the biopharmaceutical company’s stock worth $2,817,055,000 after buying an additional 348,628 shares during the last quarter. Massachusetts Financial Services Co. MA boosted its stake in Pfizer by 9.4% during the third quarter. Massachusetts Financial Services Co. MA now owns 60,207,521 shares of the biopharmaceutical company’s stock worth $1,997,083,000 after buying an additional 5,185,453 shares during the last quarter. Invesco Ltd. boosted its stake in Pfizer by 30.9% during the third quarter. Invesco Ltd. now owns 24,054,896 shares of the biopharmaceutical company’s stock worth $797,901,000 after buying an additional 5,678,004 shares during the last quarter. Finally, California Public Employees Retirement System boosted its stake in Pfizer by 0.6% during the third quarter. California Public Employees Retirement System now owns 18,380,833 shares of the biopharmaceutical company’s stock worth $609,692,000 after buying an additional 101,256 shares during the last quarter. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on PFE shares. BMO Capital Markets reissued an “outperform” rating and set a $36.00 price objective (up previously from $33.00) on shares of Pfizer in a research note on Thursday. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $45.00 price target on shares of Pfizer in a research note on Monday, April 15th. Guggenheim started coverage on Pfizer in a research note on Friday, February 23rd. They issued a “buy” rating and a $36.00 price target on the stock. Morgan Stanley upped their price target on Pfizer from $28.00 to $29.00 and gave the company an “equal weight” rating in a research note on Thursday. Finally, Argus lowered Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. Eleven investment analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to MarketBeat, Pfizer has an average rating of “Hold” and a consensus price target of $36.00.

Pfizer Stock Up 0.4 %

NYSE PFE traded up $0.11 during trading hours on Friday, hitting $27.81. 60,568,852 shares of the company were exchanged, compared to its average volume of 41,900,304. The company has a 50 day moving average of $26.88 and a two-hundred day moving average of $28.21. The company has a quick ratio of 0.69, a current ratio of 0.91 and a debt-to-equity ratio of 0.69. Pfizer Inc. has a 52-week low of $25.20 and a 52-week high of $40.37. The firm has a market cap of $157.48 billion, a price-to-earnings ratio of -463.42, a PEG ratio of 1.18 and a beta of 0.63.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Wednesday, May 1st. The biopharmaceutical company reported $0.82 earnings per share for the quarter, topping the consensus estimate of $0.56 by $0.26. Pfizer had a positive return on equity of 8.58% and a negative net margin of 0.56%. The company had revenue of $14.88 billion for the quarter, compared to the consensus estimate of $13.87 billion. During the same quarter in the prior year, the business earned $1.23 EPS. Pfizer’s revenue was down 19.5% on a year-over-year basis. Equities research analysts anticipate that Pfizer Inc. will post 2.36 earnings per share for the current year.

Pfizer Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, June 14th. Shareholders of record on Friday, May 10th will be issued a dividend of $0.42 per share. The ex-dividend date of this dividend is Thursday, May 9th. This represents a $1.68 annualized dividend and a yield of 6.04%. Pfizer’s dividend payout ratio (DPR) is -2,799.53%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.